CEN Biotech (CEN Biotech) Additional Paid-In Capital : $45.24 Mil(As of Mar. 2023)

View and export this data going back to 2016. Start your Free Trial

What is CEN Biotech Additional Paid-In Capital?

CEN Biotech's quarterly additional paid-in capital increased from Sep. 2022 ($44.92 Mil) to Dec. 2022 ($45.22 Mil) and increased from Dec. 2022 ($45.22 Mil) to Mar. 2023 ($45.24 Mil).

CEN Biotech's annual additional paid-in capital increased from Dec. 2020 ($17.07 Mil) to Dec. 2021 ($44.34 Mil) and increased from Dec. 2021 ($44.34 Mil) to Dec. 2022 ($45.22 Mil).

CEN Biotech Additional Paid-In Capital Historical Data

The historical data trend for CEN Biotech's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEN Biotech Additional Paid-In Capital Chart

CEN Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Additional Paid-In Capital

Get a 7-Day Free Trial

14.39

15.78

17.07

44.34

45.22

CEN Biotech Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Additional Paid-In Capital	Get a 7-Day Free Trial															44.34	44.75	44.92	45.22	45.24

CEN Biotech Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

CEN Biotech Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of CEN Biotech's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

CEN Biotech (CEN Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CEN Biotech Inc (OTCPK:CENBF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

3295 Quality Way, Suite 300, Windsor, ON, CAN, N8T 3R9

Website

CEN Biotech Inc is an early-stage Canadian biopharmaceutical company. The Company grows, sells, and delivers pharmaceutical-grade medical marijuana to patients.

Executives

Lawrence Lehoux	director, officer: Chief Technology Officer	11879 SOLOMAN ST, WINDSOR A6 N8P 1P1
Jeffery Allen Thomas	director	23772 WEST ROAD #152, BROWNSTOWN TOWNSHIP MI 48183
Rick Leigh Purdy	director	9 ELAINE STREET, ST. ALBERT A0 T8N7R6
Usamakh Saadikh	director	3 DRUDBGY NARODOV SQUARE, KYIV 2H 04210
Joseph A. Byrne	director, officer: Chief Executive Officer	6 CAMERON SIDE ROAD EAST, ESSEX A6 N8M 2X5
Alex Tarrabain	director	18908 89 AVENUE, EDMONTON A0 T5T 6B7
Donald Strilchuck	director	352 RIDEAU PL, TECUMSEH A6 N8N 3N9
Richard Boswell	director, 10 percent owner, officer: CFO Senior Executive VP	2408 EASTERN AVE., ROCHESTER HILLS MI 48307
Ameen Ferris	director	30 AYRSHIRE COURT, BRAMPTON A6 L6Z 0G6
Brian Payne	director, officer: Vice President	1027 HUNTINGTON BLVD, BELLE RIVER A6 N0R 1A0
Aubrey De Lavenu Harold Andre	director	APT 627 VALE DO LOBO, ALMANCIL S1 8135-034
Bahige B. Chaaban	director, 10 percent owner, officer: Chief Executive Officer	888 OLD TECUMSAH RD., BELLE RIVER A6 N0R 1A0

CEN Biotech (CEN Biotech) Headlines

From GuruFocus

CEN Biotech Inc. Announces Word Presto Partner Program

By ACCESSWIRE ACCESSWIRE • 11-08-2022

CEN Biotech Inc. Announces Planned Strategic Expansion of Business and Closing of Clear Com Media Inc. Acquisition

By ACCESSWIRE ACCESSWIRE • 07-13-2021